- Home
- ACAD vs PBH Comparison
ACAD vs PBH Comparison
Compare ACAD & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PBH
- Stock Information
- Founded
- ACAD 1993
- PBH 1996
- Country
- ACAD United States
- PBH United States
- Employees
- ACAD N/A
- PBH N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PBH Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- PBH Health Care
- Exchange
- ACAD Nasdaq
- PBH Nasdaq
- Market Cap
- ACAD 3.8B
- PBH 4.2B
- IPO Year
- ACAD 2004
- PBH 2005
- Fundamental
- Price
- ACAD $20.98
- PBH $76.33
- Analyst Decision
- ACAD Buy
- PBH Buy
- Analyst Count
- ACAD 18
- PBH 5
- Target Price
- ACAD $27.71
- PBH $94.00
- AVG Volume (30 Days)
- ACAD 2.0M
- PBH 404.5K
- Earning Date
- ACAD 08-05-2025
- PBH 08-07-2025
- Dividend Yield
- ACAD N/A
- PBH N/A
- EPS Growth
- ACAD N/A
- PBH 2.88
- EPS
- ACAD 1.37
- PBH 4.29
- Revenue
- ACAD $996,283,000.00
- PBH $1,137,762,000.00
- Revenue This Year
- ACAD $13.39
- PBH $2.04
- Revenue Next Year
- ACAD $10.59
- PBH $2.07
- P/E Ratio
- ACAD $15.33
- PBH $17.89
- Revenue Growth
- ACAD 22.42
- PBH 1.10
- 52 Week Low
- ACAD $13.40
- PBH $64.94
- 52 Week High
- ACAD $25.23
- PBH $90.04
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- PBH 24.77
- Support Level
- ACAD $20.75
- PBH $78.86
- Resistance Level
- ACAD $23.09
- PBH $80.69
- Average True Range (ATR)
- ACAD 0.78
- PBH 1.69
- MACD
- ACAD -0.20
- PBH -0.45
- Stochastic Oscillator
- ACAD 9.83
- PBH 6.78
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PBH Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.